Fourthly, the clinical utility of the cfDNA methylation model in CRC detection was compared with CEA and CA19‐9, which are not used as CRC screening biomarkers in clinical practice due to their low sensitivity. This evidence concerns the gene CEACAM5 and colorectal carcinoma.